Shots:
- The multicenter survey involves assessing Kesimpta Sensoready autoinjector pen in 80 MS patients and 50 MS nurses, with RMS who received a disease modifying treatment through a subcutaneous/intramuscular injection via an autoinjector
- The result shows MS patients and nurses prefer the Kesimpta Sensoready autoinjector pen over other autoinjectors for current treatment (84% vs 16%). The findings will be presented at the ACTRIMS Forum 2021 on Feb, 2021
- Kesimpta received positive CHMP opinion last month based on two P-III trials showed reduction of annual relapses by over 50% with more than 30% relative risk reduction of 3 mos. CDP vs teriflunomide
Click here to read full press release/ article | Ref: Novartis | Image: PMLiVE
The post Novartis Report Results of Kesimpta (ofatumumab) Sensoready autoinjector pen for Multiple Sclerosis first appeared on PharmaShots.